PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2403022

[Population kinetic program for Michaelis-Menten elimination].

M Lü·H W Zhou·J F Song
View original source ↗Export metadata ↓

Abstract

The microcomputer program, PKP-ME (population kinetic program for Michaelis-Menten elimination), is presented to estimating population pharmacokinetic parameters of drug obeying Michaelis-Menten kinetics and predicting individual pharmacokinetic parameters. A data set consisting of 69 steady-state phenytoin concentration-dosage pairs from 44 out-patients was analyzed with the present program. Five population kinetic parameters and their standard deviations were given by PKPME. The capability predicting individual phenytoin dosage was assessed by the retrospective analysis of data of 44 patients and the prospective analysis of 15 patients. A good correlation existed between predicting dose and actual dose. Population correlation coefficient was equal to 0.99 at P = 0.05.

Explore related subjects

EpilepsyHumansPhenytoinSoftwareEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Lü, H W Zhou, J F Song. 1990. [Population kinetic program for Michaelis-Menten elimination].. https://pubmed.ncbi.nlm.nih.gov/2403022/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗